EU CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
You may also be interested in...
The European Medicines Agency has recommended new uses for six approved products, including the CAR T-cell therapy Tecartus.
The European Medicines Agency has cleared the decks for the pan-EU approval of nearly a dozen new drugs. Tecvayli is headed for a conditional approval, while Nulibry is slated to get marketing authorization under exceptional circumstances.
Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.